Literature DB >> 22098491

Hypoxic hepatitis.

Jean Henrion1.   

Abstract

Hypoxic hepatitis (HH), an acute liver injury also known as 'ischaemic hepatitis' or 'shock liver', is frequently observed in intensive care units. HH is heralded by a massive but transient rise in serum aminotransferase activities caused by anoxic necrosis of centrilobular liver cells. Cardiac failure, respiratory failure and toxic-septic shock are the main underlying conditions accounting for more than 90% of cases, but HH may also occur in other circumstances. Until recently, liver ischaemia, i.e. a drop in hepatic blood flow, was considered the leading, and even the sole, hemodynamic mechanism responsible for HH, and it was generally held that a shock state was required. In reality, other hemodynamic mechanisms of hypoxia, such as passive congestion of the liver, arterial hypoxaemia and dysoxia, play an important role while a shock state is observed in only 50% of cases. Accordingly, 'ischaemic hepatitis' and 'shock liver' are misnomers. Therapy of HH depends primarily on the nature of the underlying condition. The prognosis is poor, with more than half of patients dying during the hospital stay.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22098491     DOI: 10.1111/j.1478-3231.2011.02655.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  50 in total

1.  Ischemic Hepatitis - Intercorrelated Pathology.

Authors:  Andrea Olivia Ciobanu; Leonida Gherasim
Journal:  Maedica (Bucur)       Date:  2018-03

Review 2.  [Hepatic dysfunction in patients with cardiogenic shock].

Authors:  Philipp Kasper; Frank Tacke; Hans-Michael Steffen; Guido Michels
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-09-19       Impact factor: 0.840

3.  N-acetylcysteine treats intravenous amiodarone induced liver injury.

Authors:  Matthew L Mudalel; Kartikeya P Dave; James P Hummel; Steven F Solga
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

Review 4.  Cholestatic liver (dys)function during sepsis and other critical illnesses.

Authors:  Marc Jenniskens; Lies Langouche; Yoo-Mee Vanwijngaerden; Dieter Mesotten; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2015-09-21       Impact factor: 17.440

5.  Bilirubin in the early course of venovenous extracorporeal membrane oxygenation support for refractory ARDS.

Authors:  Chiara Lazzeri; Manuela Bonizzoli; Giovanni Cianchi; Stefano Batacchi; Marco Chiostri; Giorgio Enzo Fulceri; Laura Tadini Buoninsegni; Adriano Peris
Journal:  J Artif Organs       Date:  2017-08-18       Impact factor: 1.731

6.  The renaissance man of burn surgery: Basil A. Pruitt, Jr.

Authors:  Karel D Capek; Guillermo Foncerrada; R Patrick Clayton; Michaela Sljivich; Charles D Voigt; Gabriel Hundeshagen; Janos Cambiaso-Daniel; Craig Porter; Ashley Guillory; David N Herndon
Journal:  J Trauma Acute Care Surg       Date:  2017-11       Impact factor: 3.313

7.  Melatonin treatment enhances therapeutic effects of exosomes against acute liver ischemia-reperfusion injury.

Authors:  Cheuk-Kwan Sun; Chih-Hung Chen; Chia-Lo Chang; Hsin-Ju Chiang; Pei-Hsun Sung; Kuan-Hung Chen; Yi-Ling Chen; Sheng-Yi Chen; Gour-Shenq Kao; Hsueh-Wen Chang; Mel S Lee; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 8.  [Shock liver and cholestatic liver in critically ill patients].

Authors:  A Drolz; T Horvatits; K Roedl; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-27       Impact factor: 0.840

9.  Hypoxic hepatitis and acute liver failure in a patient with newly onset atrial fibrillation and diltiazem infusion.

Authors:  Wu Deng; Laurie Farricielli
Journal:  BMJ Case Rep       Date:  2013-09-16

10.  Donor preoperative oxygen delivery and post-extubation hypoxia impact donation after circulatory death hypoxic cholangiopathy.

Authors:  Thomas J Chirichella; C Michael Dunham; Michael A Zimmerman; Elise M Phelan; M Susan Mandell; Kendra D Conzen; Stephen E Kelley; Trevor L Nydam; Thomas E Bak; Igal Kam; Michael E Wachs
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.